LNAI

Company Overview — What Does Enochian Biosciences Inc Do?

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California. Enochian Biosciences Inc (LNAI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Mark R. Dybul and employs approximately 20 people. With a market capitalization of $10M, LNAI is one of the notable companies in the Healthcare sector.

Enochian Biosciences Inc (LNAI) Stock Rating — Avoid (April 2026)

As of April 2026, Enochian Biosciences Inc receives a Avoid rating with a composite score of 19.4/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.LNAI ranks #4,353 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Enochian Biosciences Inc ranks #801 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LNAI Stock Price and 52-Week Range

Enochian Biosciences Inc (LNAI) currently trades at $0.36. The stock lost $0.05 (12.1%) in the most recent trading session. The 52-week high for LNAI is $1.66, which means the stock is currently trading -78.1% from its annual peak. The 52-week low is $0.12, putting the stock 199.9% above its annual trough. Recent trading volume was 2.4M shares, reflecting moderate market activity.

Is LNAI Overvalued or Undervalued? — Valuation Analysis

Enochian Biosciences Inc (LNAI) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 0.26x, compared to the Healthcare sector average of 23.63x — a discount of 99%. On an enterprise value basis, LNAI trades at 11.45x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Enochian Biosciences Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Enochian Biosciences Inc Profitability — ROE, Margins, and Quality Score

Enochian Biosciences Inc (LNAI) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -308.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -90.7% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LNAI Debt, Balance Sheet, and Financial Health

Enochian Biosciences Inc has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.03x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $0. Cash and equivalents stand at $624,808.

LNAI has a beta of 1.80, meaning it is more volatile than the broader market — a $10,000 investment in LNAI would be expected to move 79.8% more than the S&P 500 on any given day. The stability factor score for Enochian Biosciences Inc is 7/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Enochian Biosciences Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, Enochian Biosciences Inc reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-6M. Operating income came in at $-14M.

In Q2 2026, Enochian Biosciences Inc reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-2M. Operating income came in at $-2M.

In Q1 2025, Enochian Biosciences Inc reported revenue of $0 and earnings per share (EPS) of $0.13. Net income for the quarter was $3M. Operating income came in at $-3M.

In FY 2025, Enochian Biosciences Inc reported revenue of $0 and earnings per share (EPS) of $-1.08. Net income for the quarter was $-178M. Operating income came in at $-189M.

Over the past 8 quarters, Enochian Biosciences Inc has experienced revenue contraction from $0 to $0. Investors analyzing LNAI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LNAI Dividend Yield and Income Analysis

Enochian Biosciences Inc (LNAI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LNAI Momentum and Technical Analysis Profile

Enochian Biosciences Inc (LNAI) has a momentum factor score of 12/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 43/100 reflects moderate short selling activity.

LNAI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Enochian Biosciences Inc (LNAI) ranks #801 out of 838 stocks based on the Blank Capital composite score. This places LNAI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LNAI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LNAI vs S&P 500 (SPY) comparison to assess how Enochian Biosciences Inc stacks up against the broader market across all factor dimensions.

LNAI Next Earnings Date

No upcoming earnings date has been announced for Enochian Biosciences Inc (LNAI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LNAI? — Investment Thesis Summary

The quantitative profile for Enochian Biosciences Inc suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 20/100 indicates premium valuation. Momentum is weak at 12/100, a headwind for near-term performance. High volatility (stability score 7/100) increases portfolio risk.

In summary, Enochian Biosciences Inc (LNAI) earns a Avoid rating with a composite score of 19.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LNAI stock.

Related Resources for LNAI Investors

Explore more research and tools: LNAI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LNAI head-to-head with peers: LNAI vs AZN, LNAI vs SLGL, LNAI vs VMD.